Data from Merck Serono’s Multiple Sclerosis Portfolio to be Presented at the 62nd Annual Meeting of the American Academy of Neurology
New data on established therapy Rebif® and on investigational therapy Cladribine Tablets to be presented at AAN underscore Merck Serono’s commitment to multiple sclerosis care and research.